Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
1372 0 |
SM ISO690:2012 DUKA, Gh., ARICU, Aculina, KUCHKOVA, Kaleria, SECARA-KUȘNIR, Elena, BARBA, Alic, DRAGALIN, Ion, UNGUR, Nikon, SPENGLER, Gabriella. Synthesis, structural elucidation and biological evaluations of new guanidine-containing terpenoids as anticancer agents. In: Natural Product Research, 2019, nr. 21(33), pp. 3052-3056. ISSN 1478-6419. DOI: https://doi.org/10.1080/14786419.2018.1516658 |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Natural Product Research | ||||||
Numărul 21(33) / 2019 / ISSN 1478-6419 /ISSNe 1478-6427 | ||||||
|
||||||
DOI:https://doi.org/10.1080/14786419.2018.1516658 | ||||||
Pag. 3052-3056 | ||||||
|
||||||
Rezumat | ||||||
Using sclareol and sclareolide as starting materials, the guanidine derivatives of 12-amino-11-dihomodrimane-8α-ol and 13-amino-14,15-bis-dinorlabd-8(9)-ene were synthesized by the reaction of the corresponding amines with sodium hydrogencyanamide in ethanol–water solution. Monoacyl- and diacylguanidines were prepared from activated with N,N-carbonyldiimidazole Δ8,9-bicyclohomofarnesenoic acid by the reaction with guanidine. Their structures were confirmed by the 1H and 13C NMR, IR spectral and elemental analysis data. The compounds 12, 13 and 15 were screened for their antiproliferative and cytotoxicity activities against Colo 205, Colo 320 and MRC 5 human lung fibroblasts with respect to standard drug, Cisplatin. The compounds 12 and 15 exhibits excellent results than positive control. Hence these two compounds may be act as drug lead molecules in cancer chemotherapy. |
||||||
Cuvinte-cheie 14, 15-Bis-norlabdane, antiproliferative activity, dihomodrimane, Guanidines, synthesis, terpenoids |
||||||
|
Cerif XML Export
<?xml version='1.0' encoding='utf-8'?> <CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'> <cfResPubl> <cfResPublId>ibn-ResPubl-85247</cfResPublId> <cfResPublDate>2019-11-13</cfResPublDate> <cfVol>33</cfVol> <cfIssue>21</cfIssue> <cfStartPage>3052</cfStartPage> <cfISSN>1478-6419</cfISSN> <cfURI>https://ibn.idsi.md/ro/vizualizare_articol/85247</cfURI> <cfTitle cfLangCode='EN' cfTrans='o'>Synthesis, structural elucidation and biological evaluations of new guanidine-containing terpenoids as anticancer agents</cfTitle> <cfKeyw cfLangCode='EN' cfTrans='o'>14; 15-Bis-norlabdane; antiproliferative activity; dihomodrimane; Guanidines; synthesis; terpenoids</cfKeyw> <cfAbstr cfLangCode='EN' cfTrans='o'><p>Using sclareol and sclareolide as starting materials, the guanidine derivatives of 12-amino-11-dihomodrimane-8α-ol and 13-amino-14,15-bis-dinorlabd-8(9)-ene were synthesized by the reaction of the corresponding amines with sodium hydrogencyanamide in ethanol–water solution. Monoacyl- and diacylguanidines were prepared from activated with N,N-carbonyldiimidazole Δ<sup>8,9</sup>-bicyclohomofarnesenoic acid by the reaction with guanidine. Their structures were confirmed by the <sup>1</sup>H and <sup>13</sup>C NMR, IR spectral and elemental analysis data. The compounds 12, 13 and 15 were screened for their antiproliferative and cytotoxicity activities against Colo 205, Colo 320 and MRC 5 human lung fibroblasts with respect to standard drug, Cisplatin. The compounds 12 and 15 exhibits excellent results than positive control. Hence these two compounds may be act as drug lead molecules in cancer chemotherapy.</p></cfAbstr> <cfResPubl_Class> <cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId> <cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId> <cfStartDate>2019-11-13T24:00:00</cfStartDate> </cfResPubl_Class> <cfResPubl_Class> <cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId> <cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId> <cfStartDate>2019-11-13T24:00:00</cfStartDate> </cfResPubl_Class> <cfPers_ResPubl> <cfPersId>ibn-person-137</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2019-11-13T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-11130</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2019-11-13T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-11165</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2019-11-13T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-26924</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2019-11-13T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-11134</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2019-11-13T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-568</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2019-11-13T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-672</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2019-11-13T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-67553</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2019-11-13T24:00:00</cfStartDate> </cfPers_ResPubl> <cfFedId> <cfFedIdId>ibn-doi-85247</cfFedIdId> <cfFedId>10.1080/14786419.2018.1516658</cfFedId> <cfStartDate>2019-11-13T24:00:00</cfStartDate> <cfFedId_Class> <cfClassId>31d222b4-11e0-434b-b5ae-088119c51189</cfClassId> <cfClassSchemeId>bccb3266-689d-4740-a039-c96594b4d916</cfClassSchemeId> </cfFedId_Class> <cfFedId_Srv> <cfSrvId>5123451</cfSrvId> <cfClassId>eda2b2e2-34c5-11e1-b86c-0800200c9a66</cfClassId> <cfClassSchemeId>5a270628-f593-4ff4-a44a-95660c76e182</cfClassSchemeId> </cfFedId_Srv> </cfFedId> </cfResPubl> <cfPers> <cfPersId>ibn-Pers-137</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-137-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2019-11-13T24:00:00</cfStartDate> <cfFamilyNames>Duka</cfFamilyNames> <cfFirstNames>Gh.</cfFirstNames> <cfFamilyNames>Дука</cfFamilyNames> <cfFirstNames>Георгий</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-11130</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-11130-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2019-11-13T24:00:00</cfStartDate> <cfFamilyNames>Aricu</cfFamilyNames> <cfFirstNames>Aculina</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-11165</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-11165-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2019-11-13T24:00:00</cfStartDate> <cfFamilyNames>Kuchkova</cfFamilyNames> <cfFirstNames>Kaleria</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-26924</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-26924-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2019-11-13T24:00:00</cfStartDate> <cfFamilyNames>Secara-Kușnir</cfFamilyNames> <cfFirstNames>Elena</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-11134</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-11134-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2019-11-13T24:00:00</cfStartDate> <cfFamilyNames>Barba</cfFamilyNames> <cfFirstNames>Alic</cfFirstNames> <cfFamilyNames>Барба</cfFamilyNames> <cfFirstNames>Алик</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-568</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-568-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2019-11-13T24:00:00</cfStartDate> <cfFamilyNames>Драгалин</cfFamilyNames> <cfFirstNames>Ион</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-672</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-672-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2019-11-13T24:00:00</cfStartDate> <cfFamilyNames>Ungur</cfFamilyNames> <cfFirstNames>Nikon</cfFirstNames> <cfFamilyNames>Унгур</cfFamilyNames> <cfFirstNames>Никон</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-67553</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-67553-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2019-11-13T24:00:00</cfStartDate> <cfFamilyNames>Spengler</cfFamilyNames> <cfFirstNames>Gabriella</cfFirstNames> </cfPersName_Pers> </cfPers> <cfSrv> <cfSrvId>5123451</cfSrvId> <cfName cfLangCode='en' cfTrans='o'>CrossRef DOI prefix service</cfName> <cfDescr cfLangCode='en' cfTrans='o'>The service of issuing DOI prefixes to publishers</cfDescr> <cfKeyw cfLangCode='en' cfTrans='o'>persistent identifier; Digital Object Identifier</cfKeyw> </cfSrv> </CERIF>